cemiplimab Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival By www.news.sanofi.us Published On :: Mon, 27 Apr 2020 08:40:00 -0400 - Libtayo decreased the risk of death by 32.4% compared to chemotherapy Full Article
cemiplimab Libtayo® (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma By www.news.sanofi.us Published On :: Tue, 05 May 2020 08:25:00 -0400 Objective responses seen in 29% of patients with locally advanced basal cell carcinoma (BCC) Full Article
